XBI:NYE-SPDR® S&P Biotech ETF (USD)

ETF | Health |

Last Closing

USD 87.82

Change

+1.69 (+1.96)%

Market Cap

N/A

Volume

0.01B

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-05 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.49 (+1.01%)

USD 37.71B
FHLC Fidelity® MSCI Health Care In..

+0.72 (+1.04%)

USD 2.77B
FXH First Trust Health Care AlphaD..

+1.13 (+1.08%)

USD 1.05B
XHE SPDR® S&P Health Care Equipme..

+0.45 (+0.52%)

USD 0.20B
IDNA iShares Genomics Immunology an..

+0.53 (+2.39%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.57 (+1.87%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+1.42 (+1.47%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.39 (+1.34%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+1.03 (+1.70%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.66 (+3.42%)

USD 6.67M

ETFs Containing XBI

MATH Metalpha Technology Holdi.. 0.00 % 1.35 %

+0.16 (+0%)

USD 0.10B
INAV 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.49% 14% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.49% 14% F 29% F
Trailing 12 Months  
Capital Gain -12.29% 14% F 18% F
Dividend Return 0.13% 19% F 1% F
Total Return -12.16% 14% F 16% F
Trailing 5 Years  
Capital Gain -2.53% 19% F 39% F
Dividend Return 0.52% 26% F 1% F
Total Return -2.01% 19% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain -3.88% 14% F 16% F
Dividend Return -3.81% 14% F 10% F
Total Return 0.07% 21% F 3% F
Risk Return Profile  
Volatility (Standard Deviation) 29.04% 19% F 36% F
Risk Adjusted Return -13.12% 14% F 13% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.